Obermatt
See Similar Stocks →

Verrica Pharmaceuticals

NAQ:VRCA · US92511W2070
PharmaceuticalsSmall

360

55
Medium confidence — indicative
Profit price—
Cash yield1
Price/Sales50
EV / Gross Profit35
Price/Book88
Return on Capital14
Return on Equity100
EBIT Margin4
Gross Profitability98

Cash truth not applicable for financial companies.

Sales growth6
Profit growth49
Reinvestment18
Price momentum39
Debt load79
Debt serviceability24
Liquidity47
Analyst ratings69
Opinion Changes95
Price Target Upside89
Market mood23
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Verrica Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Based on 1/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2013
Employees76
Websiteverrica.com
ISINUS92511W2070
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
DermatologyOncologyHealth CareMedicalPharmaceutical

Description

Verrica Pharmaceuticals Inc., a therapeutics company, develops and commercializes medications for the treatment of dermatologic diseases, including skin cancers. The company’s commercial product and portfolio of product candidates are clinician admi…

Analysis

Middle-of-the-road

Verrica Pharmaceuticals Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is adequate. The company scores 20/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
29
2026

All-time high

29

Jun 2026

All-time low

20

Mar 2026

Average rank

25

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
50
—
—
—
Price/Earnings
52
—
—
—
Price/Book
88
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
76
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Verrica Pharmaceuticals with its peers
Rhythm Pharmaceuticals
NMQ:RYTM
31
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Sarepta Therapeutics
NSQ:SRPT
69
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Karyopharm Therapeutics
NSQ:KPTI
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Puma Biotechnology
NSQ:PBYI
79
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kura Oncology
NSQ:KURA
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →